GNI Group Ltd.

GNI Group Ltd. is a vertically integrated multinational biopharmaceutical company headquartered in Tokyo, Japan, founded in 2001. The company engages in the complete drug development value chain, from research and discovery through clinical development, manufacturing, and commercialization. Operating across pharmaceutical and medical device segments, GNI Group leverages its operational bases in China, Japan, the United States, and Australia to develop innovative therapies targeting unmet medical needs. The company focuses on orphan diseases and conditions prevalent in Asian markets, utilizing proprietary drug discovery platforms and cost-effective clinical trial infrastructure in China. GNI Group's pipeline includes marketed products such as Etuary for idiopathic pulmonary fibrosis, alongside advanced-stage candidates like F351 for liver fibrosis and Tamibarotene for acute promyelocytic leukemia. The company pursues both in-house research and collaborative partnerships with global pharmaceutical companies, and it owns a pharmaceutical manufacturing facility in China enabling integrated operations across drug discovery, development, manufacturing, and sales activities.